Cellectis SA CLLS.OQ, CLLS.O is expected to show a fall in quarterly revenue when it reports results on November 3 (estimated) for the period ending September 30 2025
The Paris Ile-de-france-based company is expected to report a 47.1% decrease in revenue to $9.55 million from $18.05 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Cellectis SA is for a loss of 23 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cellectis SA is $7.50, about 53.6% above its last closing price of $3.48
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.19 | -0.21 | -0.24 | Missed | -12 |
Mar. 31 2025 | -0.17 | -0.19 | -0.18 | Beat | 6.4 |
Dec. 31 2024 | -0.18 | 0.08 | Beat | 143.2 | |
Sep. 30 2024 | -0.20 | -0.21 | -0.23 | Missed | -7.9 |
Jun. 30 2024 | -0.32 | -0.30 | -0.28 | Beat | 7.8 |
Mar. 31 2024 | -0.35 | -0.33 | 0.08 | Beat | 124.2 |
Dec. 31 2023 | 0.27 | -0.22 | -0.70 | Missed | -223.5 |
Sep. 30 2023 | -0.36 | -0.42 | -0.31 | Beat | 25.4 |
This summary was machine generated October 31 at 16:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments